Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146562 | 1.00 | KMT2A (0.54) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL122155 | 1.00 | KMT2A (0.54) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL16090749 | 0.90 | KMT2A (0.54) | KMT2AL3MBTL1NPFFR1NPFFR2DRD2 | |
| SCHEMBL19121559 | 0.89 | KMT2A (0.55) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL7834998 | 0.89 | KMT2A (0.55) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL1781856 | 0.89 | KMT2A (0.55) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL3187533 | 0.89 | KMT2A (0.55) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL3187519 | 0.89 | KMT2A (0.55) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL7835003 | 0.89 | KMT2A (0.55) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 | |
| SCHEMBL19121534 | 0.88 | KMT2A (0.54) | KMT2AL3MBTL1S1PR5S1PR1NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-07-25 | — | — | US | disclosed |
| WO-2021139794-A1 | CRYSTAL FORM OF PYRROLIDINYL UREA DERIVATIVE AND APPLICATION THEREOF | 漳州片仔癀药业股份有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-20210147436-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3822266-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020011227-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | 南京明德新药研发有限公司 | 2020-01-16 | — | — | WO | disclosed |
| EP-2435037-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8497383-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497383-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120142752-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | NGF, LCK, RET | KMT2A 3826/4885L3MBTL1 3565/4885S1PR5 2115/4885 |
| US-20210147436-A1 | PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES | NGF, RET, NTRK1 | KMT2A 3479/4885L3MBTL1 4302/4885S1PR5 3468/4885 |
| US-20120142752-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PRSS1, SERPINB6 | KMT2A 1805/4885L3MBTL1 806/4885S1PR5 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.